Hemoglobinopathies Market - Forecast(2024 - 2030)

Hemoglobinopathies Market Overview

The Hemoglobinopathies Market Size is estimated to reach $14.3 billion by 2027 and it is poised to grow at a CAGR of 10.2% over the forecast period of 2022-2027. Hemoglobinopathies is a hereditary and genetic disorder that affects the structure, function or production of the key hemoglobin. Examples of hemoglobinopathies or types of hemoglobinopathies are thalassemia of alpha and beta class, sickle cell disease and hemoglobin E and C diseases amongst others. Hemoglobinopathies can be or cannot be dangerous based on criticality. Hemoglobinopathies screening is a critical aspect in understanding the criticality of the disease/condition. Hemoglobinopathies cannot be cured permanently. However, it can be treated as per the stage and medical requirements by using various therapeutics. Immunofixation analysis is a form of blood test that measures certain proteins in the blood and is a hemoglobinopathy screen. Governments of various economies across the globe are trying to understand the importance of hemoglobinopathy results or fetal hemoglobin to eradicate the condition from new-born. Rising clinical trials and activities along with support from critical health authorities are driving the Hemoglobinopathies industry in the forecast period of 2022-2027.

Hemoglobinopathies Market Report Coverage

The report: “Hemoglobinopathies Market Forecast (2022-2027)" by IndustryARC, covers an in-depth analysis of the following segments in the Hemoglobinopathies Market.

by Type: Thalassemia, Sickle Cell Disease and Other Haemoglobin (Hb) Variants.
by Diagnosis: Blood Test, Genetic Test, Prenatal Genetic Tests, Electrophoresis and Others. 
by Treatment: Blood Transfusion, Analgesics, Antibiotics, ACE Inhibitors, Gene-Therapy and Others.
by Geography: North America (the US, Canada and Mexico), Europe (Germany, the UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan India, South Korea, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

• Geographically, North America held a dominant market share in 2021. It is owing to the presence of robust healthcare infrastructure focusing on diagnostic and treatment. However, Asia-Pacific is expected to offer lucrative opportunities in the forecast period owing to the rising focus on private-public partnerships to aid the disease-afflicted population.
• The rising prevalence of disease subjugated by growing support from leading healthcare authorities propels market usage. However, failed clinical trials impede market confidence.
• A detailed analysis of the strengths, weaknesses, opportunities and threats would be provided in the Hemoglobinopathies Market Report.

Hemoglobinopathies Market Segment Analysis - by Type

The Hemoglobinopathies Market based on type can be further segmented into Thalassemia, Sickle Cell Disease and Other Haemoglobin (Hb) Variants. The sickle cell disease held a dominant market share in the year 2021 and is estimated to grow at the fastest rate, with a CAGR of 11.4% over the forecast period of 2022-2027. The dominant share is attributed to the initiatives partaken by biopharma companies and other non-profit organizations, which are excessively focusing on SCD treatment. As per NCBI 2020, an estimated 10%-40% of the individuals in many regions of Africa are carriers of the aforementioned form of sickle cell gene, which in turn has increased the prevalence to nearly 2% in the countries. As per PLOS Medicine Article, the number of sickle cell anemia is estimated to increase by about 30% globally in 2050.

Hemoglobinopathies Market Segment Analysis - by Treatment

The Hemoglobinopathies Market based on treatment can be further segmented into blood transfusion, analgesics, antibiotics, ACE inhibitors, gene therapy and others. Blood Transfusion held a dominant market share in 2021. Blood Transfusions are suggested by doctors for patients whose hemoglobin drops below 8g/dL. The frequency of blood transfusion is higher in thalassemia cases as compared to other hemoglobinopathies. The transfusion is done every 3 to 4 weeks to help maintain the normal level of blood components. However, cases of transfusion-acquired hemoglobinopathy have provided other segments to outpace the aforementioned methodology. Hence, gene therapy is estimated to be the fastest-growing segment, with a CAGR of 11.9% over the forecast period of 2022-2027. Nearly 5% of the world population carries a Hb disorder trait with gene therapy, it targets the underlying genetic cause of the condition through one-time administration and reduces the need for patients to undertake blood transfusions.

Hemoglobinopathies Market Segment Analysis - by Geography

North America held a dominant market share of 34% in 2021. The US Hemoglobinopathies tests cover a range of diagnostic measures such as CBC (Complete Blood Count), blood smear and other popular methodologies. Owing to a primal diagnosis system in the North American region, hemoglobinopathies can be cured under time constraints. As per CDC, nearly 100,000 Americans are affected by SCDs. However, Asia-Pacific is estimated to offer lucrative growth opportunities over the forecast period of 2022-2027. It is owing to the establishment of improved healthcare infrastructure in middle- and lower-income countries, supported by the leading NGO and Health Associations in the forecast period of 2022-2027.

Hemoglobinopathies Market Drivers

Increasing Prevalence of Hemoglobinopathies in Developing and Low-income Countries along with Other Regions:

As per a report by the American Society of Hematology, nearly 95% of children born in low- and middle-income countries are born with thalassemia. The prevalence of these conditions has spread through the developed nations owing to excessive migration in the timelines. The prevalence in the developing region has been a significant deterrent owing to a lack of awareness and high unmet needs in societies where daily food consumption remains a prevalent challenge. Additionally, race and ethnicity prevail a key role in increasing the prevalence. For example, 1 in every 365 African-American births has SCDs. However, the incidence for Hispanic Americans is 1 in every 16,300 births. The rising population of African-Americans would be a key propeller.

The Growing Awareness Regarding the Control of Such Conditions/Diseases:

As per WHO, in all countries of the World, plans of action to manage and control Hb disorders are needed, covering community awareness and education, training of health care professionals and infrastructure development to strengthen diagnostic and transfusion services. A holistic and cost-effective approach that includes family and population screening, a registry for epidemiological data and a preventive program that includes genetic counseling, prenatal diagnosis and preimplantation genetic diagnosis, has proven to be successful in reducing the frequency of thalassemia in many countries, globally. WHO is playing a critical role in subsiding the incidence within South-East Asia where the genetic prevalence in 2020 for thalassemia stood at 2.5-15%.

Hemoglobinopathies Market Challenge

The Failing Clinical Trials for Various Types of Hemoglobinopathies:

As per JAMA Research, an average of US$1.3 billion per drug is lost, if the clinical trial is unsuccessful. These costs are not limited to clinical trial failures and opportunity costs. The market has suffered halts in the roll-out of therapies and drugs. In August 2019, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Lastly, a critical issue for the market remains that this form of conditions doesn’t have a permanent cure - which limits market participation and confidence.

Hemoglobinopathies Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Hemoglobinopathies Industry. The top 10 companies in the Hemoglobinopathies market are:

1. Abbott Diagnostics
2. Bio-Rad Labs
3. Danaher Corporation
4. Mindray Medical International
5. Nexcelom Bioscience LLC
6. Nihon Kohden Corporation
7. PerkinElmer Inc
8. Siemens Healthineers
9. Pfizer Inc.
10. Sysmex Corporation

Recent Developments

• In September 2022, Azerbaijan Thalassemia Center and BGI China entered into a partnership to improve thalassemia screening in Azerbaijan. Such change would be adapted with the help of genetic technology. BGI’s wholly owned subsidiary - Huada Biotechnology (Wuhan) has obtained the medical device registration permission for the detection of alpha and beta thalassemia gene detection kit.
• In January 2022, Novo Nordisk entered into a definitive agreement to acquire Forma Therapeutics for nearly $1.1 billion via cash transaction.  Forma Therapeutics is a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and rare blood disorders. This addition would allow to access the market for diseases faced by a plethora of populations, primarily sickle cell disease.
• In February 2021, Mindray and Tencent AI Lab entered a framework agreement on AI Collaboration. They aimed to jointly develop AI-Assisted products for blood-cell analysis and explore the integration and the application of in-vitro diagnostics.

Relevant Titles

Cord Blood Banking Services Market - Industry Analysis, Market Share, Size, Trends, Application Analysis and Forecast Analysis.
Report Code: HCR 0886

Tissue Banking Market - Industry Analysis, Market Share, Size, Trends, Application Analysis and Forecast Analysis.
Report Code: HCR 0014

Gene Therapy Market - Industry Analysis, Market Size, Share, Trends, Application Analysis and Forecast Analysis.
Report Code: HCR 0215

For more Lifesciences and Healthcare Market reports, please click here